What reputation challenges are unique to pharmaceutical companies?

Pharmaceutical companies face a reputation problem defined by asymmetry: tight regulatory limits on what they can say about their own products, and almost no limit on what patients, critics, advocacy groups, and now AI engines say about them. Several challenges follow. Regulatory constraints on claims mean the company often cannot respond to a narrative as directly as it would like, so the work emphasizes scrupulously accurate, compliant content. Scientific accuracy is non-negotiable, since errors carry both regulatory and safety consequences. Patient-advocacy dynamics cut both ways and require genuine engagement rather than spin. And AI-driven medical misinformation is the newest and fastest-moving risk, because models synthesize confident answers about drugs from a mix of authoritative and unreliable sources. We monitor those answers with AIQ™ across pipeline, safety, and outcome prompts, because in pharma the gap between what the company is allowed to say and what the engines are saying about it is exactly where reputation is won or lost.